174890-58-5Relevant articles and documents
Making method of t-butyloxycarboryl-3-(hydroxymethyl)-[1,2,3]triazole[1,5-a]piperidine-6-amide
-
, (2017/10/13)
The invention relates to a synthesis method of t-butyloxycarboryl-3-(hydroxymethyl)-[1,2,3]triazole[1,5-a]piperidine-6-amide. The technical problem that a suitable industrial synthesis method does not exist at present is mainly solved. The synthesis method is divided into the following seven steps of firstly making (2-chloro-5-nitropyridine) and t-butyl ethyl malonate react in a solvent tetrahydrofuran under the action of NaH to obtain a compound 2; obtaining a compound 3 from the compound 2 under the action of trifluoroacetic acid; afterwards, subjecting the compound 3 to a hydrogenation reaction under the catalysis of palladium carbon to obtain a compound 4; carrying out t-butyloxycarboryl protection on the compound 4 to obtain a compound 5; making the compound 5 act with p-ABSA (p-Acetamidobenzenesulfonyl Azide) under the action of DBU (1,8-Diazabicyclo[5,4,0]undec-7-ene) to obtain a compound 6; reducing the compound 6 in the tetrahydrofuran by lithium aluminium tetrahydride to obtain a compound 7; subjecting the compound 7 to catalytic hydrogenation under the catalysis of wet palladium carbon to obtain a final compound 8.
QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR INHIBITORS
-
, (2014/12/09)
Compounds of formula (Ι') that are Fibroblast Growth Factor Inhibitors (FGFR) and are therefore useful for the treatment of diseases treatable by inhibition of FGFR are disclosed. Also disclosed are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
Use of EP4 receptor ligands in the treatment of IL-6 involved diseases
-
Page 103, (2010/02/06)
Methods of treating IL-6 involved diseases with EP4 receptor ligands, including EP4 receptor antagonists. Assays to determine the effect of test compounds on PGE2-induced whole blood cells activation.